Navigation Links
Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
Date:10/26/2011

EMERYVILLE, Calif., Oct. 26, 2011 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that enrollment has started to the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba™ (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

The Phase 3, multicenter, double-blind, placebo-controlled, randomized clinical trial evaluating Menerba is currently open for enrollment. A total of 50 clinical sites in the U.S. will enroll 1,200 postmenopausal women between the ages of 40 and 65 years. Participants will be randomized to Menerba 5g/day, Menerba 10g/day or placebo and treated for 12 weeks. The primary aims of the study are to determine the safety and efficacy of two doses of Menerba compared to placebo after 12 weeks of treatment.  Efficacy will be measured by the reduction of moderate to severe hot flushes from baseline to 12 weeks of treatment. Dr. Wulf Utian, Executive Director Emeritus and Honorary Founding President of the North America Menopause Society and Professor Emeritus at Case Western Reserve University is serving as the Principal Investigator for the study.

"We have had a very busy and productive year preparing for today's important launch of the late stage clinical trial in the field of women's health. As predicted from our vast toxicology data and the mechanism of action, we showed that higher doses of Menerba were very safe and demonstrated a level of efficacy similar to hormone therapy. Today we are proceeding with our first pivotal Phase 3 trial of Menerba with great optimism and enthusiasm. We are elated to be one step closer to providing a truly novel agent for the treatment of menopausal hot flashes to the 40 million women in need of
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
2. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
3. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
4. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
5. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
6. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
7. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
8. Bionovo Announces 2010 Highlights and Year-End Financial Results
9. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
10. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
11. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th ... laboratory which has developed the AMAS cancer test, is making ... Chicago.  To date, the test, which is a serum-based in ... is emerging as a significant tool in the fight against ... With an estimated 17 million cancer survivors in ...
(Date:7/28/2014)...  Serco Inc., a provider of professional, technology, ... awarded a re-compete contract to support the Navy ... Medical Systems.  Serco will provide deployable medical systems ... healthcare to meet warfighter and humanitarian requirements in ... five year contract has a one-year base period ...
(Date:7/28/2014)... , July 28, 2014 Southern ... Tipton , Ph.D., President and CEO of Southern ... Controlled Release Society (CRS) for the 2014-2015 term.  ... meeting on July 12 in Chicago ... countries.  The Controlled Release Society ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
(Date:7/28/2014)... Maureen Salamon ... News) -- Infants and children who are at risk ... be vaccinated against the infection, according to updated recommendations ... And routine vaccinations for the potentially deadly ... American Academy of Pediatrics says. In its first ...
(Date:7/28/2014)... News) -- British researchers report that an alternative to ... In their experiments, the scientists found that clasping ... person to the other than what is known as ... might suffice as a cultural substitute for the firm ... the August issue of the American Journal of ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... heart rhythm irregularities are more likely to get a pacemaker ... fact, the study of more than 16,000 people found that ... to get a pacemaker than those without the memory-robbing condition. ... folks with dementia are so much more likely to be ...
(Date:7/28/2014)... 28, 2014 SIMpalm helped its ... App is available on iTunes for download . Experience ... Audio Chef allows you to listen and cook along with ... way: simply get out the ingredients and equipment, press play, ... or prepare ingredients ahead of time, just relax and cook ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4
... in post-menopausal women after they stopped taking combined hormone ... will be reported in the March 5 edition of ... Rowan T. Chlebowski, M.D., Ph.D., a Los Angeles Biomedical ... the study. , This latest study reinforces the original ...
... N.C., March 4 DARA BioSciences(TM),(Nasdaq: DARA ... Drutz, MD to the,Board of Directors. Dr. Drutz ... serve on the Company,s Compensation Committee as well ... effective February,26, 2008., Richard Franco, Sr., DARA,s ...
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), today announced it ... 2008, after the U.S. markets close. ISTA will,host a ... and provide a commercial and pipeline update at 5:00 ... live conference call, U.S. and Canadian participants may,dial 866-831-6270; ...
... Initiative points to continued need for mammograms , , TUESDAY, ... cancer lingers after a woman stops taking combination hormone replacement ... in the March 5 issue of the Journal of ... the landmark Women,s Health Initiative (WHI). That trial was halted ...
... 2,500 researchers and professionals in the area of biomolecular science ... Conference & Exhibition of the Society for Biomolecular Sciences (SBS) ... advances in biotechnology, challenges and automation solutions in the field. ... years meeting include: , New Methods ...
... March 4 Perrigo Company,(Nasdaq: PRGO ; ... 20 mg,Omeprazole delayed released tablets to its retail ... same dose as Prilosec OTC(R). Under terms,of an ... is,the exclusive marketer and distributor for the store ...
Cached Medicine News:Health News:LA BioMed researcher says 'unexpected' increase in cancer risk found 2Health News:DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Specialists in drug discovery and development convene 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 3
The DSL-10-3000 ACTIVE Ferritin Enzyme-Linked Immunosorbent (ELISA) Kit provides materials for the quantitative measurement of ferritin in serum....
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
Medicine Products: